Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Design and rational for the precision medicine guided treatment for cancer pain pragmatic clinical trial.

Mosley SA, Hicks JK, Portman DG, Donovan KA, Gopalan P, Schmit J, Starr J, Silver N, Gong Y, Langaee T, Clare-Salzler M, Starostik P, Chang YD, Rajasekhara S, Smith JE, Soares HP, George TJ Jr, McLeod HL, Cavallari LH.

Contemp Clin Trials. 2018 May;68:7-13. doi: 10.1016/j.cct.2018.03.001. Epub 2018 Mar 10.

2.

CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial.

Smith DM, Weitzel KW, Elsey AR, Langaee T, Gong Y, Wake DT, Duong BQ, Hagen M, Harle CA, Mercado E, Nagoshi Y, Newsom K, Wright A, Rosenberg EI, Starostik P, Clare-Salzler MJ, Schmidt SO, Fillingim RB, Johnson JA, Cavallari LH.

Genet Med. 2019 Jan 23. doi: 10.1038/s41436-018-0431-8. [Epub ahead of print]

PMID:
30670877
3.
4.

Clinical application of pharmacogenetics in pain management.

Smith DM, Weitzel KW, Cavallari LH, Elsey AR, Schmidt SO.

Per Med. 2018 Mar;15(2):117-126. doi: 10.2217/pme-2017-0032. Epub 2018 Jan 31.

5.

Palliative Treatment of Cancer-Related Pain [Internet].

Kongsgaard U, Kaasa S, Dale O, Ottesen S, Nordøy T, Hessling SE, von Hofacker S, Bruland ØS, Lyngstadaas A.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2005 Dec.

6.

Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).

Pergolizzi J, Böger RH, Budd K, Dahan A, Erdine S, Hans G, Kress HG, Langford R, Likar R, Raffa RB, Sacerdote P.

Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23.

PMID:
18503626
8.

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study).

Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Terashima M, Yoshida T, Sakai K, Otake Y, Koyama A, Nishio K, Nakagawa K.

BMC Cancer. 2017 Oct 6;17(1):674. doi: 10.1186/s12885-017-3664-z.

9.

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin WJ Jr.

Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.

10.

Effect of Opioid vs Nonopioid Medications on Pain-Related Function in Patients With Chronic Back Pain or Hip or Knee Osteoarthritis Pain: The SPACE Randomized Clinical Trial.

Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ES, Kroenke K, Bair MJ, Noorbaloochi S.

JAMA. 2018 Mar 6;319(9):872-882. doi: 10.1001/jama.2018.0899.

11.

Use of pharmacogenetic data to guide individualized opioid prescribing after surgery.

Rocco R, Thiels CA, Ubl DS, Moyer AM, Habermann EB, Cassivi SD.

Surgery. 2019 Jul 15. pii: S0039-6060(19)30292-2. doi: 10.1016/j.surg.2019.04.033. [Epub ahead of print]

PMID:
31320226
12.

Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients.

Lemberg KK, Heiskanen TE, Neuvonen M, Kontinen VK, Neuvonen PJ, Dahl ML, Kalso EA.

Scand J Pain. 2010 Jan 1;1(1):24-33. doi: 10.1016/j.sjpain.2009.09.003.

PMID:
29913934
13.

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.

Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P.

Cochrane Database Syst Rev. 2018 Jun 5;6:CD006332. doi: 10.1002/14651858.CD006332.pub3. Review.

14.

Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study.

Campbell G, Hall WD, Peacock A, Lintzeris N, Bruno R, Larance B, Nielsen S, Cohen M, Chan G, Mattick RP, Blyth F, Shanahan M, Dobbins T, Farrell M, Degenhardt L.

Lancet Public Health. 2018 Jul;3(7):e341-e350. doi: 10.1016/S2468-2667(18)30110-5.

15.

The Burden of Opioid-Induced Constipation: Discordance Between Patient and Health Care Provider Reports.

LoCasale RJ, Datto C, Wilson H, Yeomans K, Coyne KS.

J Manag Care Spec Pharm. 2016 Mar;22(3):236-45. doi: 10.18553/jmcp.2016.22.3.236.

16.

Prescription of Controlled Substances: Benefits and Risks.

Preuss CV, Kalava A, King KC.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-.
2019 May 10.

17.

Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain.

Wiffen PJ, Derry S, Moore RA.

Cochrane Database Syst Rev. 2014 May 29;(5):CD011056. doi: 10.1002/14651858.CD011056.pub2. Review.

18.

Personalized oxycodone dosing: using pharmacogenetic testing and clinical pharmacokinetics to reduce toxicity risk and increase effectiveness.

Linares OA, Daly D, Linares AD, Stefanovski D, Boston RC.

Pain Med. 2014 May;15(5):791-806. doi: 10.1111/pme.12380. Epub 2014 Feb 12.

PMID:
24517173
19.

Pharmacogenomic considerations in opioid analgesia.

Vuilleumier PH, Stamer UM, Landau R.

Pharmgenomics Pers Med. 2012;5:73-87. doi: 10.2147/PGPM.S23422. Epub 2012 Aug 23. Erratum in: Pharmgenomics Pers Med. 2013;6:1.

20.

Hydromorphone for cancer pain.

Bao YJ, Hou W, Kong XY, Yang L, Xia J, Hua BJ, Knaggs R.

Cochrane Database Syst Rev. 2016 Oct 11;10:CD011108. Review.

Supplemental Content

Support Center